160 related articles for article (PubMed ID: 28459510)
1. Yiguanjian cataplasm attenuates opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
Gao S; Gao H; Fan Y; Zhang G; Sun F; Zhao J; Li F; Yang Y; Wang K
J Tradit Chin Med; 2016 Aug; 36(4):464-70. PubMed ID: 28459510
[TBL] [Abstract][Full Text] [Related]
2. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
Rehni AK; Bhateja P; Singh TG; Singh N
Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological modulation of leukotriene D(4) attenuates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
Rehni AK; Singh I; Singh N; Bansal N; Bansal S; Kumar M
Eur J Pharmacol; 2008 Nov; 598(1-3):51-6. PubMed ID: 18840427
[TBL] [Abstract][Full Text] [Related]
4. Modulation of histone deacetylase attenuates naloxone-precipitated opioid withdrawal syndrome.
Rehni AK; Singh N; Rachamalla M; Tikoo K
Naunyn Schmiedebergs Arch Pharmacol; 2012 Jun; 385(6):605-19. PubMed ID: 22362134
[TBL] [Abstract][Full Text] [Related]
5. Potential involvement of tyrosine phosphatase and calpain-related pathways in opioid withdrawal syndrome in mice.
Rehni AK; Singh N
Behav Pharmacol; 2012 Jun; 23(3):302-9. PubMed ID: 22495184
[TBL] [Abstract][Full Text] [Related]
6. Modulation of src-kinase attenuates naloxone-precipitated opioid withdrawal syndrome in mice.
Rehni AK; Singh N
Behav Pharmacol; 2011 Apr; 22(2):182-90. PubMed ID: 21285874
[TBL] [Abstract][Full Text] [Related]
7. Disulfiram attenuates morphine or methadone withdrawal syndrome in mice.
de Cordé A; Krząścik P; Wolińska R; Kleczkowska P; Filip M; Bujalska-Zadrożny M
Behav Pharmacol; 2018 Aug; 29(5):393-399. PubMed ID: 29462108
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro attenuation of naloxone-precipitated experimental opioid withdrawal syndrome by insulin and selective KATP channel modulator.
Singh P; Sharma B; Gupta S; Sharma BM
Psychopharmacology (Berl); 2015 Jan; 232(2):465-75. PubMed ID: 25059539
[TBL] [Abstract][Full Text] [Related]
9. Neuropeptide trefoil factor 3 attenuates naloxone-precipitated withdrawal in morphine-dependent mice.
Wu P; Shi HS; Luo YX; Zhang RX; Li JL; Shi J; Lu L; Zhu WL
Psychopharmacology (Berl); 2014 Dec; 231(24):4659-68. PubMed ID: 24825609
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological modulation of geranylgeranyltransferase and farnesyltransferase attenuates opioid withdrawal in vivo and in vitro.
Rehni AK; Singh TG
Neuropharmacology; 2013 Aug; 71():19-26. PubMed ID: 23415632
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
[TBL] [Abstract][Full Text] [Related]
13. Ammonium pyrrolidine dithiocarbamate and RS 102895 attenuate opioid withdrawal in vivo and in vitro.
Rehni AK; Singh N
Psychopharmacology (Berl); 2012 Mar; 220(2):427-38. PubMed ID: 21931991
[TBL] [Abstract][Full Text] [Related]
14. Suppression of naloxone-precipitated withdrawal jumps in morphine-dependent mice by stimulation of prostaglandin EP3 receptor.
Nakagawa T; Minami M; Katsumata S; Ienaga Y; Satoh M
Br J Pharmacol; 1995 Nov; 116(6):2661-6. PubMed ID: 8590986
[TBL] [Abstract][Full Text] [Related]
15. Effects of alkaloid-rich extract from Mitragyna speciosa (Korth.) Havil. on naloxone-precipitated morphine withdrawal symptoms and local field potential in the nucleus accumbens of mice.
Cheaha D; Reakkamnuan C; Nukitram J; Chittrakarn S; Phukpattaranont P; Keawpradub N; Kumarnsit E
J Ethnopharmacol; 2017 Aug; 208():129-137. PubMed ID: 28687506
[TBL] [Abstract][Full Text] [Related]
16. Effects of tizanidine administration on precipitated opioid withdrawal signs in rats.
Pinelli A; Trivulzio S; Spezia R
Drug Alcohol Depend; 1998 Mar; 50(1):81-8. PubMed ID: 9589275
[TBL] [Abstract][Full Text] [Related]
17. Effects of opioid agonist and antagonist in dams exposed to morphine during the perinatal period.
Sobor M; Timár J; Riba P; Friedmann T; Király KP; Gyarmati S; Al-Khrasani M; Fürst S
Brain Res Bull; 2011 Jan; 84(1):53-60. PubMed ID: 20934489
[TBL] [Abstract][Full Text] [Related]
18. Morphine restores and naloxone-precipitated withdrawal depresses wheel running in rats with hindpaw inflammation.
Morgan MM; Ataras K
Pharmacol Biochem Behav; 2021 Oct; 209():173251. PubMed ID: 34363827
[TBL] [Abstract][Full Text] [Related]
19. Brain reward deficits accompany naloxone-precipitated withdrawal from acute opioid dependence.
Liu J; Schulteis G
Pharmacol Biochem Behav; 2004 Sep; 79(1):101-8. PubMed ID: 15388289
[TBL] [Abstract][Full Text] [Related]
20. Endothelin ETA receptor antagonist reverses naloxone-precipitated opioid withdrawal in mice.
Bhalla S; Pais G; Tapia M; Gulati A
Can J Physiol Pharmacol; 2015 Nov; 93(11):935-44. PubMed ID: 26440527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
